Doctors Are Writing Fewer Benzodiazepine Prescriptions. The Counterfeits Are Getting Stronger.

Matthew White took lorazepam, the anti-anxiety pill sold as Ativan, at about 3 mg a day for more than 20 years, exactly as prescribed. When he stopped, he writes in a first-person account posted to the Benzodiazepine Information Coalition’s site, he spent about a week in inpatient detox, left by ambulance with chest pain (his heart tested healthy), and in his first week at a recovery center had what he describes as benzodiazepine-induced psychosis: he could not tell reality from his own thoughts. A week in, he woke at 2 a.m. unable to move his left side, sure it was a stroke. White is a pharmacist. He is also one man writing about himself, and we cannot independently verify his account. But if you have ever tried to come off one of these pills, none of it will sound exaggerated.

Cutting the prescription is not the same as treating the dependence, and the street will happily cover the difference.

That is our read of two sets of numbers that rarely appear in the same sentence. One says doctors are handing out far fewer benzodiazepines. The other says what is being sold outside the pharmacy is changing fast. What sits between them, the people who were physically dependent and got cut off, is the number nobody has.

Fewer pills from the pharmacy is real, and defensible

Benzodiazepines are the family of sedative pills that includes Xanax, Valium, Ativan and Klonopin. They quiet anxiety and induce sleep by turning up the brain’s main braking system. The catch is physical dependence, which just means your body adjusts to the drug being there and punishes you when it leaves. In a study in the American Journal of Psychiatry, Rutgers researcher Naomi Cruz and colleagues analyzed more than 1.1 billion prescription fills from 2013 to 2024 and found dispensing fell 26.7%, and the average dose per fill fell 18.3%. The steepest drop was among adults 18 to 29. Primary care doctors and psychiatrists wrote fewer; nurse practitioners and physician assistants wrote more. Cruz’s own reading is measured: “Our findings suggest that prescribing practices may have become more cautious or selective over the past decade.”

The caution has a basis. In September 2020 the FDA ordered a stronger boxed warning on the whole class, stating that physical dependence can develop when the drugs are taken steadily for days to weeks, even as prescribed, and that stopping abruptly or cutting the dose too fast can cause withdrawal reactions, including seizures that can be life-threatening. The same notice flags the combination with opioids, alcohol and other drugs as the setting where misuse turns into overdose.

Read the limits as carefully as the headline. The study counts fills at pharmacies. It cannot say why prescribers changed, and it cannot say what happened to the patients whose prescriptions shrank or stopped. Nobody has shown that those patients are the ones buying counterfeits. What the data shows is that one door narrowed. It says nothing about who was standing behind it.

What is being sold on the other side

The other door is not static. Aegis Sciences, a toxicology lab, reports in its 2026 mid-year summary that bromazolam, a lab-made cousin of Xanax that never went through drug approval, accounted for 68% of designer-benzodiazepine detections in 2025. Federal regulators put it in Schedule I in December 2025. By the second quarter of 2026 its share had slipped to nearly 50%, while others climbed: ethylbromazolam from just over 6% to about 8%, desalkylgidazepam from just under 2% to just over 4%. Remove one compound and the market reaches for the next. That is Aegis’s testing, from its own client base, and the page does not report how many tests sit behind the percentages, so it describes the mix in its lab rather than in any particular city.

The most urgent version arrived this week, and it is in Dublin, not Phoenix. On October 10 the Irish Medical Times reported that Prof Eamon Keenan, the national clinical lead for addiction services at Ireland’s health service, told RTÉ Radio that a new, unnamed benzodiazepine significantly stronger than Valium or Xanax has been linked to several overdoses in Dublin this week, sold in blister packs that Keenan said “look very legitimate.” People on opioid replacement therapy face an even higher risk. We do not know that this drug is in the United States. We do know the packaging trick, and that a pill that looks like it came from a pharmacy tells you nothing about what is in it.

We do not know that this drug is in the United States.

We have been here before, and we blamed the wrong thing

From the late 1960s until 1982, Valium was the best-selling prescription drug in America. The Rolling Stones called it “Mother’s Little Helper.” By 1979 the country had found its panic: Senate hearings that year put Valium on the front pages at a time when the fear was usually heroin or cocaine. Historian David Herzberg points out in that account what made it different. This was a middle-class drug, prescribed legally by respectable doctors to respectable patients. The country argued about prescribers and about housewives and whether the pill was liberation or a leash. The hearings ended. The people who had been taking the drug for years were still dependent the morning after. The prescribing numbers fell, and we called that progress. A taper, a slow stepwise reduction under a clinician’s eye, is the part of the story that never made the headlines, and we are in danger of repeating the omission.

What White says was missing

The most useful part of White’s account is not the horror. It is the list of what went wrong inside a system built for something else. He took his medication as prescribed and did not see himself as someone with an addiction, yet the recovery center asked him to introduce himself that way and attend AA-style meetings every day. He describes being expected to manage his own medications while impaired, a chaotic, overstimulating environment that made his symptoms worse, and monitored phone calls that made it hard to speak plainly with his wife. What helped, in his telling: his wife’s calls at all hours, medical care for the cardiac and neurological scares, time, and learning that many symptoms were part of withdrawal rather than new diseases. If a story like that rings a bell, we wrote about another version of the same mismatch from a different medication.

He also lays out how recovery tends to unfold in phases: a first two weeks of anxiety, insomnia and tremor; weeks two to six of broken sleep and fatigue; a stretch from six to twelve weeks of lingering anxiety and mental fog; then months of improving thinking and sleep, with flare-ups under stress. It is one person’s framework, not a clinical standard. But a 2022 internet survey of 1,207 people in Therapeutic Advances in Psychopharmacology found symptoms of tapering and discontinuation that ranged from anxiety and insomnia to irregular heart rhythms and balance problems. That survey is self-selected, so it cannot tell you how common any of this is. It does tell you that White was not alone in what he felt.

What to do this week

If you are a clinician or program lead: pull the list of patients on long-term benzodiazepines before anyone touches a dose, and write a taper plan with a named person responsible for it, because the FDA warning is explicit that going too fast risks seizures. Add one question to intake: where are your benzodiazepines coming from now, and are they from a pharmacy? Ask it without judgment, and ask it of everyone on methadone or buprenorphine first. Check whether your lab’s panel can detect designer benzodiazepines at all. If you run a program with daily meeting requirements, ask whether a patient with a prescribed-dependence history is being told to say words that are not true for them.

If you are the one on the pills, and a prescription ended or is ending: you are not weak and you are not an outlier. Stopping cold is the dangerous option, and a taper is a medical procedure, not a test of will. Ask for it in writing, ask who to call at 2 a.m., and if you cannot get a straight answer, Rize’s Find Treatment tool can help you look for a program that treats prescribed dependence as exactly that. Naloxone does not reverse a benzodiazepine, but it does reverse the opioid that is often in the same pill or the same pocket, and it is still yours to carry.

Stopping cold is the dangerous option, and a taper is a medical procedure, not a test of will.

White’s heart was fine. His wife’s voice on the phone at two in the morning is what he credits. Build that before you cut the pill.